Nickel(II) bis(benzimidazolin-2-ylidene) complexes of the general formula [NiBr 2 (NHC) 2 ] (NHC = 1,3-dibenzylbenzimidazolin-2-ylidene, 7; NHC = 1,3-diisopropylbenzimidazolin-2-ylidene, 8; NHC = 1,3-dibenzhydrylbenzimidazolin-2-ylidene, 9; NHC = 1,3-diisobutylbenzimidazolin-2-ylidene, 10; NHC = 1-isopropyl-3-benzylbenzimidazolin-2-ylidene, 11; NHC = 1-benzhydryl-3-benzylbenzimidazolin-2-ylidene, 12 ) have been prepared and fully characterized by spectroscopic methods and single-crystal X-ray structure analyses. All complexes adopt a square-planar geometry with nickel as the crystallographic inversion center and a trans arrangement of the carbene ligands. For complexes 11 and 12, bearing unsymmetrically substituted ligands, only the trans-anti configuration was found in the solid state. In addition, the structures of 8, 9, 11, and 12 reveal a fixed orientation of the N -isopropyl and N -benzhydryl substituents with the C−H groups pointing to the nickel(II) center to maximize rare intramolecular C−H···Ni anagostic or preagostic interactions. The large downfield shift of these C−H protons in the 1 H NMR spectrum compared to their precursor salts indicates that these interactions are retained in solution. Preliminary catalytic studies show that complexes 7 − 12 are active in the Ullmann coupling of bromobenzene and 4-bromoanisole. In particular, complexes 8, 9, and 12, with sterically more demanding ligands, exhibit the best catalytic activities. The coupling reaction was found to be successful when carried out in neat [Bu 4 N]Br as ionic liquid, but not in dry DMF or in DMF with [Bu 4 N]Br as an additive.
No takes yet. Share an insight, caveat, or question.
Huynh et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: